Today we announced positive topline results from our Phase 1 study of DARE-PDM1, our investigational product designed to deliver diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), vaginally via our proprietary hydrogel to treat primary dysmenorrhea, or painful menstruation. At Daré, we’re committed to advancing a portfolio of differentiated product candidates that address meaningful unmet needs in women’s health. The data from this Phase 1 study, which evaluated the pharmacokinetics, safety and exploratory efficacy of DARE-PDM1, support its continued clinical development as well as its potential as a first-in-category product, delivering diclofenac in a convenient vaginal format that may extend the duration of pain relief and reduce the risks associated with the oral delivery of NSAIDs. Learn more about DARE-PDM1: https://lnkd.in/ea6h2ZiH
